Harpoon Therapeutics (HARP) Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to complete an ongoing Phase 1 clinical trial with data to support the next phase of development.
Harpoon Therapeutics (HARP) Provides an Update on the HPN217 Development and Deal with AbbVie (ABBV) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. The Agreement, which will terminate effective October 12, 2023, g
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has